Nexalin Technology, Inc. NXL
Biotechnology: Electromedical & Electrotherapeutic Apparatus · IPO 2022 · data as of November 13, 2026
Nexalin Technology, Inc. (NXL) is a healthcare company listed in the US with a market value of about $2M. In the twelve months to September 30, 2026 it had revenue of $277307 and net income of -$9M, a net margin of -3380.6%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is track record (0/5).
Key numbers: a P/E of 0.2, a 5-year average ROIC of -127%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 64% below the current price.
About Nexalin Technology
Nexalin Technology is listed in the US and classified in biotechnology: electromedical & electrotherapeutic apparatus, IPO year 2022. Revenue went from $144065 in 2021 to $301647 in 2025, growth of about 20.3% a year. It was profitable in 0 of the last 5 years in our data. Its share count rose by 194% over three years (dilution for shareholders). It spends 359% of revenue on research and development.
Score: 1.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $277307 | $301647 | $168721 | $110748 | $1M | $144065 |
| Net income | -$9M | -$8M | -$8M | -$5M | -$2M | -$6M |
| Free cash flow | — | — | — | — | -$2M | -$1M |
| EPS (diluted) | $7.07 | $-0.50 | $-0.83 | $-0.63 | $-0.30 | — |
| Net margin | -3380.6% | -2725.8% | -4508.7% | -4197.6% | -128.5% | -4218.9% |
| ROIC | — | -176.9% | -166.7% | -140.1% | -24.0% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $15.00, 914% above the current price; targets range from $15.00 to $15.00; the consensus rating is “none”; expected EPS is $-11.42 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Nexalin Technology’s P/E ratio?
About 0.2, based on the last twelve months of diluted earnings per share.
Is Nexalin Technology stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 64% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Nexalin Technology pay a dividend?
Not currently.
Is Nexalin Technology a good stock to buy?
We do not give buy or sell advice. Nexalin Technology scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.